We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Destiny Pharma Plc | DEST | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 18.25 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 18.25 | 18.25 | 18.25 | 18.25 | 18.25 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 26/4/2024 12:23 by sev22 A link to yesterday's Investor Meet Company Presentation - Final Results. |
Posted at 25/4/2024 08:39 by idomeneo No licensing deal for XF-73 nasal: Despite engaging with potential partners and receiving positive feedback, Destiny Pharma has not been able to secure a licensing deal for XF-73 nasal that they believe provides fair value to the company and its shareholders. This lack of a deal could be seen as a setback by investors.Uncertainty about the future of XF-73 nasal: The company is now undertaking a review of strategic options to determine how best to advance XF-73 nasal through Phase 3 clinical trials. This review introduces uncertainty about the future development path of the product, which could make investors nervous. Potential need for additional financing: As part of the strategic review, Destiny Pharma is considering the possibility of securing finance to enable it to conduct the Phase 3 clinical studies itself. This suggests that the company may need to raise additional funds, which could dilute existing shareholders or be seen as a risk if the financing is not secured. Perception of the commercial potential of antibiotics: The announcement mentions that potential partners have expressed concerns about the prevailing perceptions of the commercial potential of antibiotics. This could indicate a broader market sentiment that may be affecting the valuation of companies working in this space. While the announcement also highlights some positive developments, such as the partnership with Sebela Pharmaceuticals and the potential cost savings from a new clinical trial design for XF-73 nasal, the overall tone of the update seems to have introduced more uncertainty and potential challenges, which could explain the negative market reaction. |
Posted at 12/4/2024 08:45 by henley2 You either sell up, or if you can remain an investor in an unquoted company.You have to wonder wtf Rudd and Tovey are up to and why the Nomad is not forcing them to make a statement regarding the share price movement! |
Posted at 08/4/2024 17:22 by wh1spa Hopefully someone will ask at the Investor Meet whether or not there is a chance of this going private???? With REDX in mind! |
Posted at 28/3/2024 11:42 by john henry TBH i can see many young Biotech stocks going private,Unfortunately UK investors will not see the growth. |
Posted at 07/3/2024 11:05 by cyberbub Just filter them, some people never left primary school in their minds. Not worthy of any decent investors' time to get involved in their playground name-calling. Certainly don't respond - it only gives them the attention they crave. |
Posted at 15/2/2024 14:23 by bones698 Not looking very clueless now am I. This is heading to 30p. How you can call anyone clueless after all your raping at way higher prices is beyond belief but I've come to expect that from amateurs on these bbs.The fcay is over 90% of small shares will lose investors money yet everyone thinks they have picked a winner. How many are sat on losses here now I wonder |
Posted at 08/2/2024 19:19 by ttlance Fundraise in August, share price will be decimated when it happens. I truly believe there will be no transformational XF-73 deal. This will drift over the coming months, we will see some rises but this will be MMs sucking in investors thinking the tide has turned. |
Posted at 02/2/2024 19:38 by ttlance Amazing how sentiment has changed here. Only 2 weeks ago there was massive optimism, lording TC and highlighting how XF-73 was going to change the infection market. Investors have been truly suckered into this stock. Investors enjoying the share price rise in the last 9 months have put their own narrative to this, thinking it was a one way bet. |
Posted at 22/1/2024 17:57 by 2cmb Investors Arab3. I would call them investors with patience. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
